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Abstract
The role of rectal culture-guided antimicrobial prophylaxis (TAP) in reducing infectious com-
plications (IC) after transrectal-ultrasound prostate biopsy (TRUSPBx) is conflicting. We
assessed the prevalence of IC in a cohort of men at high risk for IC submitted to TRUSPBx
and treated with either TAP or empirical prophylaxis (EAP). Data from 53 patients at high
risk for IC undergoing TRUSPBx were collected. Patients who did not receive a rectal swab
(RS) were treated with EAP with fluoroquinolones (FQs). Of those who received the RS,
patients with FQ-susceptible organisms received ciprofloxacin while those with FQ-resistant
organisms received TAP. Office visits were scheduled to investigate the rate of complication
at day 7 and 30 after TRUSPBx. Comorbidities were scored with the Charlson Comorbidity
Index (CCI). Descriptive statistics and logistic regression models detailed the association
between clinical parameters and IC rate. Out of 53 men, 17 (32.1%) had RS while 36
(67.9%) did not. All RS cultures were positive for E. Coli and 4 (23.5%) reported FQ-resis-
tant pathogens. Considering risk factors for IC, no difference was found in terms of CCI, rate
of diabetes, UTIs or recent antibiotic utilization between groups. Overall, 12 (22.6%) men
reported IC, with a greater proportion of them belonging to the group treated with EAP
(30.6% vs 5.9%; p = 0.045). Of these, 9 (25.0%) patients, all treated with EAP, developed
post biopsy UTIs. E. Coli sustained all UTIs and 7 (77.7%) were FQ resistant. At multivari-
able analysis, CCI1, a history of UTIs/prostatitis and recent antibiotic utilization (all
p<0.04) were the most powerful predictors for ICs. In conclusion, we found that compared to
EAP, TAP significantly reduces ICs, in men at high risk for post TRUSPBx IC. Patients at
risk for IC, especially those with recent antibiotic utilization, CCI1 and a history of UTIs/
prostatitis before biopsy, could benefit from TAP.
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Introduction
Prostate cancer (PCa) is the most common non-skin cancer in elderly males in Europe. Trans-
rectal ultrasound-guided prostate biopsy (TRUSPBx) is currently the standard tissue-sampling
technique for the histological diagnosis of PCa, with over one million patients undergoing
biopsy each year in the United States [1]. Even if TRUSPBx is generally considered a safe pro-
cedure, it may be accompanied by clinical complications ranging from pain, haematospermia
and haematuria to severe infectious complications such as urinary tract infections (UTIs),
prostatitis and sepsis [2]. Studies have shown high rates of post TRUSPBx infectious complica-
tions (PTICs), with evidence of an increasing trend [2,3]. Escherichia Coli (E. coli) is the most
commonly implicated pathogen in PTICs, present in 75–90% of cases [4].
Antimicrobial prophylaxis has shown high efficacy in reducing PTICs [5] and fluoroquino-
lones (FQs) are the current first-line recommended antibiotics. However, infectious complica-
tions due to FQ-resistant organisms have increased in recent years [6,7] and FQ-resistant
organisms are becoming a significant health problem. Indeed, pre-biopsy rectal cultures have
demonstrated a FQ-resistant colonization rate of 10% to 22% [8,9].
The first step for PTIC prevention is a preoperative assessment of risk factors for resistant
bacteria [10]. Risk factors include the exposure to antimicrobials within six months prior to
biopsy and the presence of FQ-resistant bacteria [9,11]. Hospital employees and international
travellers to areas where FQ resistance is endemic are also at increased risk for infection
[12,13]. Moreover, prior prostate biopsy may be another risk factor for infectious complica-
tions, though this claim has been disputed [14].
Rectal swab (RS) cultures are used to determine the presence of FQ-resistant flora prior to
TRUSPBx [15,16]. Previous studies investigating the role of RS-guided targeted antimicrobial
prophylaxis (TAP) before TRUSPBx in reducing PTICs have found similar but not unanimous
results [17–19]. Importantly, these studies applied TAP to all patients, regardless of pre-exist-
ing risk factors for PTICs.
Concerns exist regarding the necessity, logistics, and cost-effectiveness of performing RS
cultures in all patients, but a selected approach for men with known risk factors may have ben-
efits [16]. To the best of our knowledge, no prospective studies have evaluated the effectiveness
of RS-guided prophylaxis in preselected at-risk populations. To address this gap, we performed
a cross-sectional study evaluating the effectiveness of TAP in reducing infectious complica-
tions after TRUSPBx in a selected cohort of patients at high risk for PTICs.
Materials and Methods
Patients
The analyses were based on retrospective data from a cohort of 53 consecutive white-European
individuals submitted to TRUSPBx for the suspicion of PCa between October 2015 and May
2016 at a single academic clinic. An additional 7 patients were enrolled in the study but ulti-
mately excluded due to incomplete data collection. Patients seen between October 2015 and
February 2016 underwent a RS culture and received TAP based on results, as per the standard
of care during that period. Patients seen between March 2016 and May 2016 received EAP
(500mg ciprofloxacin 2 hours before and 12 hours after the procedure) without undergoing a
rectal swab, according to a change in the standard protocol of the clinic. Each individual
patients were enrolled only once during the course of the study. Inclusion criteria were: the
presence of one or more known risk factors for PTICs [10] (Fig 1) and the absence of UTIs at
the time of biopsy. Pre biopsy UTIs were documented by culture. A history of travel was
defined as international travel within six months prior to biopsy. Antimicrobial use was
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defined as oral or intravenous antimicrobial therapy (specifically fluoroquinolones, first-, sec-
ond-, and third-generation cephalosporins and aminoglycoside) within the six months preced-
ing biopsy (taken for at least seven days continuatively).
A detailed medical history was collected. Health-significant comorbidities were scored with
the Charlson Comorbidity Index [20] as either continuous or categorized variables (CCI; cate-
gorized 0 vs1). Body mass index (BMI) was also considered for each patient using the cut-
offs proposed by the National Institutes of Health. Rectal swabs were collected in the clinic 10
days before the biopsy to allow adequate time for results. No patients refused to undergo the
indicated RS. For FQ resistance testing, swabs were directly cultured on both MacConkey agar
with 1 μg/mL ciprofloxacin and on blood agar plates and incubated at 35˚C for 48 hours. Anti-
biotic susceptibilities were determined using the automated Vitek2 machine. Growth on both
regular MacConkey and MacConkey with ciprofloxacin indicated presence of FQ-resistant
Enterobacteriaceae species. All FQ-resistant isolates were further characterized (identification
and antimicrobial susceptibilities on the Vitek-2 using GN and AST-GN25 cards). The combi-
nation MacConkey and MacConkey with ciprofloxacin plates detected 100% of Enterobacter-
iaceae isolates that tested intermediate or resistant to ciprofloxacin (MIC2ug/mL) on the
Vitek2, including ESBL-producing isolates.
Fig 1. Risk factors for post TRUSPBx infectious complications.
doi:10.1371/journal.pone.0170319.g001
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Patients with FQ-sensitive microorganisms isolated by RS received FQs prophylaxis based
on the EAP protocol, while those with FQ-resistant organisms received a TAP, for which the
isolates were susceptible, developed by Infectious Diseases physicians. All patients complied
with the prescribed prophylactic therapy. All patients received a Fleet enema the night before
the procedure. All patients underwent dipstick urinalysis the same day of the procedure, before
TRUSPBx to confirm nitrite negative, leukocyte esterase-negative urine. In case of positive
results, patients were excluded from the study. All biopsies were performed by the same expe-
rienced urologist (with an experience of more than 100 biopsies) in an outpatient setting.
Before TRUSPBx, local anaesthesia was administered transrectally. Prostate biopsies (18 cores)
were taken using an automated biopsy gun with a disposable 18 gauge x 30cm biopsy needle.
When clinically indicated (in the case of metastatic prostate cancer or saturation biopsy), 24
biopsy cores were taken. All patients were instructed to return to the emergency department of
the same hospital if they developed post-biopsy complications. Urine culture was performed 7
days after the procedure. Follow-up visits for the evaluation of possible complications were
scheduled 7 and 30 days after TRUSPBx as per standard clinic protocol. Complications were
divided into two groups. Minor complications were defined as expected side effects of
TRUSPBx, causing minimal or no discomfort, and requiring no additional treatment. Major
complications were defined as adverse effects causing significant discomfort, disability, or
requiring additional treatment. PTICs included postoperative fever >38˚C, UTIs, prostatitis,
bacteremia and sepsis. Symptomatic UTIs were defined according to EAU guidelines [21].
Prostatitis were clinically defined as frequent urge to urinate, difficulty urinating, chills and
fever, pain the genitalia/pelvic area and painful digital rectal examination.
Ethical approval
Data collection was carried out following the principles outlined in the Declaration of Hel-
sinki; after being approved by the San Paolo Hospital Ethical Committee, all patients signed an
informed consent agreeing to supply their own anonymous data for this and future studies.
Statistical analyses
Data are presented as means (SD; ranges). The statistical significance of differences in means
and proportions was tested with the one-way analysis of variance (ANOVA) and Pearson chi-
square test, respectively. A 95% confidence interval was estimated for the association of cate-
gorical parameters. Exploratory analyses were initially applied to all variables; variables were
retained for analysis when deemed clinically significant to the results. We performed logistic
regression analysis on the cohort of men who received EAP to determinate the most powerful
predictor of PTICs among the well-known risk factors (Fig 1) reported in our cohort of men.
Logistic regression univariable analysis (UVA) and multivariable analysis (MVA) tested the
associations between predictors and PTICs. Statistical analyses were performed using SPSS sta-
tistical software, v 13.0 (IBM Cor., Armonk, NY, USA). All tests were two sided, with a signifi-
cance level set at 0.05.
Results
Complete data collection was available for 17 (32.1%) patients who received RS and 36 (67.9%)
who did not received RS (-RS) before TRUSPBx.
Table 1 details patient characteristics and descriptive statistics of the entire cohort. No dif-
ferences in terms of age, BMI and mean PSA value were observed between groups. Overall,
PCa was found in 32 (60.4%) individuals with no difference between groups. All RS cultures
were positive for E. Coli and 4 (23.5%) contained FQ-resistant pathogens. Patients with FQ
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resistance received Trimethoprim-Sulfamethoxazole 800+160 mg 2 h before and 6 h after the
procedure.
Table 2 lists descriptive statistics in terms of risk factors for infectious complications and
post TRUSPBx complication rates for the entire cohort of men. CCI scores were similar for
the TAP vs EAP group (p = 0.08). Likewise, no differences in rates of diabetes mellitus,
healthcare workers or a history of previous TRUSPBx were seen between groups. Out of 53
patients, 16 (30.2%) and 19 (35.8%) men reported antibiotic utilization and a history of
UTIs/prostatitis in the 6 months preceding biopsy, respectively, with no difference between
Table 1. Characteristics and descriptive statistics of patients (No. = 53).
Overall Rectal Swab Non-swab p value (F)*
No. of patients [No. (%)] 53 (100) 17 (32.1) 36 (67.9)
Age (years) 0.36 (0.83)
Mean (SD) 69.2 (7.2) 70.5 (4.4) 68.6 (8.1)
Range 54–82 62–81 54–82
Categorized age [No. (%)] 0.13 (χ2, 5.56)
50–60 8 (15.1) 0 (0.0) 8 (15.1)
61–70 23 (43.4) 10 (18.9) 43 (5.2)
71–80 17 (32.1) 6 (11.3) 11 (20.8)
81 5 (9.4) 1 (1.9) 4 (7.5)
BMI (kg/m2) 0.23 (1.46)
Mean (SD) 25.3 (3.0) 26.0 (3.1) 24.9 (3.0)
Range 17.8–33.1 20.5–33.1 17.8–31.1
Categorized BMI [No. (%)] 0.51 (χ2, 1.32)
18.5–24.9 24 (45.3) 6 (35.1) 18 (50.0)
25–29.9 25 (47.2) 9 (52.9) 16 (44.4)
30 4 (7.5) 2 (11.8) 2 (5.6)
PSA (ng/ml) 0.41 (0.69)
Mean (SD) 13.1 (19.7) 16.4 (29.7) 11.6 (12.9)
Range 1.9–130.0 4.3–130.0 1.9–68.1
Prostate Volume (ml) 0.82 (0.05)
Mean (SD) 63.2 (38.7) 64.9 (27.7) 62.3 (43.3)
Range 14.0–234.0 27.0–120.0 14.0–234.0
Prostate Adenoma (ml) 0.69 (0.16)
Mean (SD) 31.7 (24.4) 33.7 (18.7) 30.8 (26.9)
Range 5.0–143.0 12.0–66.0 5.0–143.0
Biopsy results [No. (%)] 0.66 (χ2, 0.19)
PCa 32 (60.4) 11 (64.7) 21 (58.3)
Benign 21 (39.6) 6 (35.3) 15 (41.7)
Biopsy Gleason Score [No. (%)] 0.32 (χ2, 1.97)
6 17 (53.1) 4 (36.4) 13 (61.9)
7 8 (25.0) 4 (36.4) 4 (19.0)
8 7 (21.9) 3 (27.3) 4 (19.0)
Biopsy cores [No. (%)] 0.13 (χ2, 2.32)
18 46 (86.8) 13 (76.5) 33 (91.7)
24 7 (13.2) 4 (23.5) 3 (8.3)
BMI = body mass index; PSA = Prostate Specific Antigen; PCa = Prostate Cancer;
*P value according to chi-square test or analysis of variance (ANOVA), as indicated
doi:10.1371/journal.pone.0170319.t001
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groups. None of the men included in the study reported recent travel to locations known for
high rates of FQ-resistance or a positive anamnesis for immunosuppression (e.g steroids,
chemotherapy, HIV).
Hematospermia (18/53; 34%) and haematuria (14/53; 26.4%) were the most prevalent post
TRUSPBx minor complications among patients. No differences in terms of minor complica-
tions were seen between groups. Overall, pain and urinary retention after biopsy were reported
by only 4 (7.5%) and 3 (5.6%) patients. Post biopsy fever was more frequently reported by—RS
patients (33.3% vs 5.9%; p = 0.03). Overall, 12 (22.6%) men reported PTICs, with a greater pro-
portion of them belonging to the—RS group (30.6% vs 5.9%; p = 0.045). Of these, 9 (25.0%)
patients, all belonging to the—RS group, developed post biopsy UTIs. E. coli sustained all
UTIs and 7 (77.7%) were FQ resistant. According to guidelines, patients who developed PTICs
were treated with third-generation cephalosporins, based on antimicrobial susceptibility.
Three patients developed prostatitis after the procedure (2 of them sustained by E. coli and 1
sustained by Klebsiella sp.) and were treated with third-generation cephalosporins. Only 4
(7.5%) patients required hospitalization for PTICs with no differences between groups. No
cases of sepsis occurred after biopsy.
Table 3 reports UVA and MVA analyses assessing the association between predictors and
PTICs.
Table 2. Characteristics and descriptive statistics [No. (%)] of patients (No. = 53).
Overall Rectal Swab (N. = 17) Non-swab (N. = 36) p value (χ2)*
Risk factors for infectious complications
CCI 0.08 (F = 3.24)
Mean (SD) 1.1 (1.2) 1.3 (1.1) 0.6 (1.2)
Range 0.0–6.0 0.0–3.0 0.0–6.0
CCI 0.17 (1.85)
CCI 0 29 (54.7) 7 (41.2) 22 (61.1)
CCI1 24 (45.3) 10 (58.8) 14 (38.9)
Diabetes Mellitus 5 (9.4) 3 (17.6) 2 (5.6) 0.16 (1.97)
UTIs/Prostatitis 16 (30.2) 6 (35.3) 10 (27.8) 0.58 (0.31)
Previous TRUSPBx 8 (15.1) 4 (23.5) 4 (11.1) 0.24 (1.38)
Healthcare workers 9 (17.0) 4 (23.5) 5 (13.9) 0.38 (0.76)
Recent antibiotic use 19 (35.8) 8 (47.1) 11 (30.6) 0.24 (1.36)
Post TRUSPBx minor complications
Haematuria 14 (26.4) 4 (23.5) 10 (27.8) 0.74 (0.11)
Rectal bleeding 2 (3.8) 0 (0.0) 2 (5.6) 0.32 (0.98)
Hematospermia 18 (34.0) 5 (29.4) 13 (36.1) 0.63 (0.23)
Post TRUSPBx major complications
Pain 4 (7.5) 2 (11.8) 2 (5.6) 0.42 (0.63)
Urinary retention 3 (5.6) 0 (0.0) 3 (8.3) 0.22 (1.50)
Fever > 38˚C 13 (24.5) 1 (5.9) 12 (33.3) 0.03 (4.70)
Infectious complications 12 (22.6) 1 (5.9) 11 (30.6) 0.04 (4.02)
UTIs 9 (17.0) 0 (0.0) 9 (25.0) 0.02 (5.12)
Prostatitis 3 (5.6) 1 (5.9) 2 (5.6) 0.96 (0.02)
Hospitalization 4 (7.5) 0 (0.0) 4 (11.1) 0.15 (2.04)
CCI = Charlson Comorbidity Index; UTIs = Urinary tract infections; TRUSPBx = Transrectal ultrasound-guided prostate biopsy
*P value according to chi-square test or analysis of variance (ANOVA), as indicated
doi:10.1371/journal.pone.0170319.t002
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According to UVA, CCI1, a history of UTIs/prostatitis and recent antibiotic utilization
were significantly associated with PTICs (all p<0.05). At MVA, CCI1 (OR 7.08, p = 0.04), a
history of UTIs/prostatitis (OR 6.13, p = 0.04) and recent antibiotic utilization (OR 5.53,
p = 0.02) were the only independent predictors for PTICs, after accounting for diabetes melli-
tus, being a healthcare worker and a history of previous TRUSPBx.
Discussion
This study was designed to evaluate PTIC prevalence in a selected cohort of men at high risk
for infectious complications after prostate biopsy who received a RS culture and subsequent
TAP, compared to a group of same-risk men not receiving RS and treated with EAP before
TRUSPBx. Of clinical importance, patients treated with EAP reported higher rates of PTICs
compared to those treated with TAP. Importantly, 23.5% of patients with RS culture results
were found to have FQ-resistant E. coli. Moreover, recent antibiotics utilization, CCI1 and a
history of UTIs/prostatitis before biopsy were the most powerful predictors for PTICs.
Our interest was fuelled by increasing evidence regarding the role of RS-guided prophylaxis
in reducing PTICs. Given the increasing trend of infectious complications due to FQ-resistant
organisms [6,7], antimicrobial prophylaxis using RS culture shows promise to deliver several
advantages. However, the benefits of TAP and its impact on PTICs, in comparison with EAP,
are still debated. One study looking at this issue found no differences between men treated
with TAP and those treated with EAP [18], others have shown that TAP results in fewer infec-
tious complications than EAP yet with differences that failed to reach significance [22–24],
while yet others [17,25] did find significant differences in the incidence of PTICs between men
receiving TAP and patients treated with EAP prior to biopsy. More recently, a systemic review
of the literature reported that PTIC and sepsis rates were significantly higher in men receiving
EAP, compared to those treated with RS-guided TAP [19]. Overall, although multiple studies
have found a reduction of PTICs when RS and TAP are used in the general population of men
undergoing TRUSPBx, this difference has not always reached significance.
To the best of our knowledge, no studies have investigated the benefit of RS-guided TAP in
a cohort of patients specifically selected based on their high risk for PTICs. We found that
high-risk patients treated with EAP more frequently reported PTICs, compared to those
treated with TAP. Furthermore, 23.5% of the RS cultures revealed FQ-resistant E. coli. This
data is in line with previous studies showing increasing rates of PTICs owing to FQ-resistant
bacteria [16], with rates of FQ-resistant E. coli ranging from 13% to 22% [16]. This finding is
Table 3. Logistic regression models predicting post TRUSPBx infectious complications in patients who were not submitted to rectal swab
(n = 36).
Infectious complications
UVA model MVA model
OR (95% CI) P value OR (95% CI) P value
CCI1 4.31 (1.10–6.93) 0.03 7.08 (1.02–9.43) 0.04
Diabetes Mellitus 0.84 (0.08–8.823 0.88 0.31 (0.01–7.70) 0.48
+UTIs/Prostatitis 4.97 (1.27–9.50) 0.02 6.13 (1.04–6.32) 0.04
Previous TRUSPBx (Yes vs no) 0.44 (0.05–3.99) 0.46 0.14 (0.01–2.63) 0.19
Healthcare workers 0.97 (0.17–5.43) 0.97 0.25 (0.03–2.40) 0.23
Recent antibiotic use 4.34 (1.12–6.75) 0.03 5.53 (1.43–7.54) 0.02
UVA = Univariate model; MVA = Multivariate model, TRUSPBx = Transrectal ultrasound-guided prostate biopsy; CCI = Charlson Comorbidity Index;
UTIs = Urinary tract infections
doi:10.1371/journal.pone.0170319.t003
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of primary importance because statistical models predicted that by 2013 the rate of FQ-resis-
tant E. coli would have been as high as 45% in populations with high FQ usage [26]. Neverthe-
less, FQs are still the most commonly prescribed antibiotic prophylaxis prior to TRUSPBx [15]
and pharmaceutical companies currently have no new antibiotics in the pipelines to replace
oral FQs.
The necessity and cost-effectiveness of performing RS cultures in all men prior to TRUSPBx
have been debated. Studies have demonstrated cost-savings of up to 4,499 USD per averted
PTIC [18], but have also reported that anywhere between 27 and 45.7 men from the general
population must be screened to prevent one PTIC [18,19,27]. However, a selected approach
for men with known risk factors may have increased benefits [16], especially considering that
results from previous cost-benefit reports are difficult to generalize. This is because the local
prevalence of FQ-resistant bacteria will play a crucial role in the calculation of whether TAP is
cost-efficient in a given region [28]. Moreover, the cost of medical care varies by region. Here,
we clearly demonstrate the benefits of RS-guided TAP in reducing PTICs in our selected
cohort of men at high-risk for infectious complications. Thus, in order to render TAP both
effective and cost-efficient, the selection of patients who could benefit from TAP, via the iden-
tification of risk factors for developing PTICs, may be of major importance.
The most common risk factor for PTICs is exposure to antimicrobials within six months
prior to biopsy [9]. Moreover, aside from known risk factors for PTICs including diabetes,
immunosuppression, and urological factors [6], hospital employees and international travel-
lers to areas where FQ resistance is endemic are also at increased risk [12,13]. A history of pre-
vious prostate biopsies is another risk factor, albeit highly debated, for PTICs [16,24]. In our
MVA we found that recent antibiotic utilization, CCI1 and a history of UTIs/prostatitis
before biopsy were the most powerful predictors for PTICs. These clinical conditions should
thus be carefully considered, especially for patients at high risk for PTICs, in order to select
patients who would benefit from TAP.
This study is, to date, the first to examine the impact of TAP in a selected cohort of men
with well-known risk factors for developing PTICs; whereas previous studies on this topic
have focused on the general population of men and have shown conflicting results. This study
was conducted with a rigorous methodology while previous studies have shown various meth-
odological limitations. Some previous studies examined only the prevalence of severe compli-
cations and ignored minor, more frequent, infectious complications or had a short follow up
period, thus leading to an underreporting of PTICs [29]. In our study, rather, we assessed both
major and minor PTICs and used a long follow up period. An inadequate registration method
in previous studies could also have led to underreported infectious complications. The use of
direct patient contact through a telephone call or a follow-up consultation is certainly more
accurate than electronic medical records in the identification of PTICs [29].
Our study is not devoid of limitations. It was conducted with a relatively small, homoge-
nous cohort of men and thus deserves external validation with an independent, larger and
more diverse sample. Although the characteristics of the groups were similar, we cannot
exclude unknown confounding factors. We did not perform a cost effectiveness analysis but
we clearly demonstrated the significant impact of TAP in reducing PTICs in men with risk fac-
tors for infection after biopsy, identifying a specific group of patients who could most benefit
from RS-guided prophylaxis. The retrospective nature of the study is another limitation. Also,
the dipstick analysis performed on every patient to confirm nitrite negative and leukocyte
esterase-negative urine cannot be considered as accurate as urine culture. However, current
EAU guidelines did not recommend urine culture before TRUSBx [21]. Finally, as described
above, patients may harbor multiple strains of both FQ-sensitive and FQ-resistant rectal flora,
dictating consideration for repeated longitudinal screening [30].
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Conclusion
This cross-sectional study provides new clinically-relevant evidence that RS-guided prophy-
laxis significantly reduces PTICs compared to EAP in a cohort of men at high risk for infec-
tious complications. Importantly, 23.5% of patients with RS culture results were found to have
FQ-resistance E. coli. Moreover, recent antibiotic utilization, CCI1 and a history of UTIs/
prostatitis before biopsy emerged as the most powerful predictors for PTICs. Overall, the
current results indicate a clinical need for comprehensive investigations of potential risk fac-
tors for PTICs in order to select candidates who would benefit most form TAP, keeping in
mind the extraordinary epidemiological and socio-economical impact of these infectious
complications.
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